These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 18206214

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New treatments for SLE: cell-depleting and anti-cytokine therapies.
    Anolik JH, Aringer M.
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R, Albert D.
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [Abstract] [Full Text] [Related]

  • 5. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.
    Murdaca G, Colombo BM, Puppo F.
    Autoimmun Rev; 2011 Nov; 11(1):56-60. PubMed ID: 21835271
    [Abstract] [Full Text] [Related]

  • 6. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R, Anolik JH.
    Drugs; 2006 Nov; 66(15):1933-48. PubMed ID: 17100405
    [Abstract] [Full Text] [Related]

  • 7. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I.
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies.
    Lee HJ, Sinha AA.
    Autoimmunity; 2006 Sep; 39(6):433-44. PubMed ID: 17060022
    [Abstract] [Full Text] [Related]

  • 15. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?
    Stohl W, Looney RJ.
    Clin Immunol; 2006 Oct; 121(1):1-12. PubMed ID: 16697258
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC, St Clair EW.
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [Abstract] [Full Text] [Related]

  • 19. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T.
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.